Leukemia, Lymphocytic, Chronic Clinical Trial
Official title:
Phase II Study of Rituximab Plus B-Glucan in Patients With Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. CLL is a
cancer of the B-lymphocytes, which make antibodies that help protect the body against harmful
foreign substances, such as bacteria and viruses. Similar to CLL, small lymphocytic lymphoma
(SLL) is a less-common cancer of the B-lymphocytes. In SLL, the abnormal lymphocytes mainly
affect the lymph nodes; in CLL, the abnormal lymphocytes mainly affect the blood and bone
marrow.
Current drug therapies for CLL/SLL are known to increase the severity of pre-existing low
blood cell counts, which in turn increase the risk of infections in patients. Research to
improve the safety and effectiveness of CLL/SLL therapy is currently ongoing. One such
therapy being investigated is Rituximab.
Rituximab is a type of drug known as a therapeutic antibody. Therapeutic antibodies are
laboratory-created substances that attach onto a protein on the surface of a cell. After
binding to the cell, the therapeutic antibody can block the growth of the tumor and/or
trigger the body's immune system to attack the target, and can also sensitize a cancer cell
to chemotherapy. Rituximab is approved by the Food and Drug Administration (FDA) for the
treatment of CLL/SLL.
Beta-Glucan (Imucell WGP) is an over-the-counter dietary supplement that enhances the body's
immune system. ImucellTM WGP is extracted from food-grade baker's yeast, which is permitted
for use in food by the FDA. Animal studies have shown that Imucell WGP helps trigger the
white blood cells to destroy cancer cells. Other animal studies combining Rituximab with
Imucell WGP have shown greater tumor regression and tumor-free survival.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03204188 -
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
|
Phase 2 | |
Completed |
NCT02758665 -
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
|
Phase 2 | |
Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
Completed |
NCT00562224 -
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
|
Phase 1 | |
Completed |
NCT00186303 -
Transplantation for Patients With Chronic Lymphocytic Leukemia
|
N/A | |
Completed |
NCT00270049 -
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
|
Phase 2 | |
Terminated |
NCT02440685 -
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00083473 -
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT04030195 -
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
|
Phase 1/Phase 2 | |
Completed |
NCT00464633 -
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 | |
Completed |
NCT00055146 -
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 | |
Not yet recruiting |
NCT05154474 -
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
|
||
Completed |
NCT00289549 -
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 | |
Terminated |
NCT01045382 -
MSC and HSC Coinfusion in Mismatched Minitransplants
|
Phase 2 | |
Terminated |
NCT01050946 -
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
|
Phase 2 | |
Completed |
NCT00283101 -
A Safety Study in Patients With Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT00546793 -
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
|
Phase 1/Phase 2 | |
Terminated |
NCT00167180 -
Post Transplant Donor Lymphocyte Infusion
|
Phase 2 | |
Completed |
NCT00535912 -
Phase III Study Treatment of CLL B and C
|
Phase 3 |